Mad Money Mailbag: Grab Amgen on the Pullback

A viewer learns why Cramer still likes this biotech company.
Author:
Publish date:

Editor's note: The following are questions received from viewers of "Mad Money," seen every day at 6 p.m. EST on CNBC.

Amgen (AMGN) - Get Report has dropped 10% on the year. Do you still like the stock?-- Lois from Massachusetts

James J. Cramer:

In my opinion, this company remains the best of breed in biotech. It's very rare to find a great franchise like this trading at just 20 times expected full-year earnings. With that in mind, I believe Amgen is attractive to purchase on this pullback.

What is the deal with Dow Chemical (DOW) - Get Report? The company posted record profits, but the stock is sinking.-- Javier from Texas

James J. Cramer:

I was equally dumbfounded, wondering why the company was trading at just 8 times expected full-year earnings. Then I noticed that the company boosted its dividend today -- for the first time in several years -- sending the yield up toward 4%. In my opinion, that is quite a bargain.

Along those lines, my colleague David Peltier follows Dow for

TheStreet.com's

Dividend Stock Advisor. Check out his newsletter for more information on Dow, and other insights on dividend investing.

Please tell me why a stock like JP Morgan (JPM) - Get Report gets upgraded one week and downgraded the next?-- Lee from Alabama

James J. Cramer:

The financials are turning into a real battleground in this environment. I'm in the bullish camp here, and have recently been buying

Wells Fargo

(WFC) - Get Report

for my charitable trust,

Action Alerts PLUS.

As for JP Morgan, I believe that Jamie Dimon still has his work cut out for him, trying to integrate the Bank One purchase.

Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by

clicking here

.